ABUS vs LLY · P/E 5.4, rev $6.2M vs P/E 39, rev $65.18B
Arbutus Biopharma Corp (ABUS) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the ABUS and LLY stock pages for the full models.
Not investment advice.